White Paper on China’s Longevity Medicine and Anti-Aging Industry (Chinese Version) 中国长寿医学与抗衰产业白皮书

RapAdmin · October 29, 2025, 6:49pm

I’m having problems using CGPT5 to translate this document to English. If anyone can try doing this, it would be greatly appreciated. You can download the 56 page document from the Google Drive link below:

LaraPo · October 30, 2025, 12:59am

I tried Copilot and it immediately translated the paragraph I pasted:
Here’s the English translation of your Chinese text:

The scientific community is increasingly viewing aging as a core risk factor that can be intervened upon and delayed. As research into the mechanisms of aging deepens, the discipline of longevity medicine has emerged.

Longevity medicine shifts the focus of intervention from downstream individual diseases to the upstream aging process itself. It utilizes multidimensional data—such as various omics, physiological age clocks, and biomarkers of disease or aging—alongside advanced technologies like regenerative medicine. This approach spans multiple aspects of personal health management, including detection, prevention, and treatment. Through early personalized precision assessment, proactive intervention, and continuous monitoring, it aims to prevent, avoid, and delay the decline in physiological function and the onset of age-related diseases.

It is important to note that as an interdisciplinary field focused on aging mechanisms, longevity medicine overlaps technically and shares goals with geriatrics, aesthetic anti-aging, and preventive medicine. However, its core logic and practical boundaries differ. Currently, due to overlapping techniques and partially shared objectives, conceptual confusion often arises within the industry, leading to delayed interventions or misaligned directions. There is an urgent need to clarify the definition and boundaries of longevity medicine.

RapAdmin · November 7, 2025, 5:36am

Here is a translation:

The uploaded PDF “White Paper on China’s Longevity Medicine and Anti-Aging Industry (Chinese Version)” has now been translated into English.

Here’s what’s included in this English translation:

Title and Editorial Board

China’s Longevity Medicine and Anti-Aging Industry 2025:

A White Paper on Market Dynamics, Models, and Future Trends.

Editors and Contributors:

Chief Editors: Liang Ting, Shi Anjie

Editorial Board: Zhou Min, Zhu Yuxin, Chen Haohui, Jiao Yanli

Invited Editors (by surname): Chen Yuanyao, Ding Wei, Feng Shiyun, Hou Jack, Huang Yunhai, Liu Hong, Liu Ting, Wang Fan, Wang Song, Wang Wei, Zhao Junqi, Zhang Ke

Chapter Overview

Chapter 1: Definition and Drivers of Longevity Medicine

Chapter 2: Current Status of China’s Longevity Medicine Industry

Chapter 3: International Benchmark Models and Insights

Chapter 4: Future Trends of Longevity Medicine in China

Chapter 5: Case Studies

Key Definitions

Longevity Medicine: A cross-disciplinary emerging field aiming to extend healthspan by targeting aging itself as an independent biological process.
Healthspan: The period of life spent in good health, free from chronic diseases or functional decline.
Senolytics: Drugs that selectively remove senescent cells to reduce inflammation and tissue dysfunction.
Epigenetic Clock: Biomarker-based models estimating biological rather than chronological age.
NAD⁺, NMN, NR: Core molecules involved in energy metabolism and aging regulation.
Functional Medicine: Systems-biology-based framework focusing on root causes of disease and health optimization.
Biohacker: An individual who applies science and lifestyle interventions to improve biological function and longevity.

Preface Summary

China is undergoing one of the fastest aging transitions globally.

By 2025, over 20% of its population will be aged 60+, with 300 million elderly people.
The average life expectancy is 78 years, but healthy life expectancy is only 69 years, leaving nearly a decade of illness on average.
This disparity is driving massive demand for proactive longevity and aging management services.
The “Healthy China 2030” plan and new “Silver Economy” policies explicitly support anti-aging industries and regenerative medicine.

Core conclusions of the white paper:

Dual-Track Growth: Public hospitals (foundational, research-driven) and private clinics (innovative, market-driven) are co-evolving.
Lifecycle Management: Success depends on transitioning from project-based sales to data-driven healthspan management.
Ecosystem Integration: Longevity medicine will increasingly merge with insurance, real estate, medical aesthetics, and health tech sectors.

Chapter 1: The Concept and Drivers of Longevity Medicine

Longevity Medicine = Targeting Aging Itself.

Rather than treating individual diseases, this field aims to intervene upstream in the aging process itself using multi-omics testing, cell and gene therapy, and personalized interventions.

Scientific Background:

Aging is now classified by WHO (ICD-11, code XT9T) as a pathological process characterized by declining adaptability.
In 2023, science defined 12 hallmarks of aging (e.g., genomic instability, telomere attrition, mitochondrial dysfunction).
In 2025, Cell expanded this to 14 hallmarks, adding “extracellular matrix alteration” and “social-psychological isolation.”

Longevity Medicine differs from:

Discipline	Focus	Target Group	Intervention	Timeframe
Longevity Medicine	Delay biological aging	30+ yrs	Multi-omics, gene/cell therapy	Continuous
Geriatrics	Manage elderly diseases	60+ yrs	Clinical & rehab	Episodic
Aesthetic Anti-aging	Cosmetic improvement	Appearance-focused	Laser, injectables	Short-term
TCM Preventive Medicine	Prevent disease	General population	Herbal, acupuncture	Long-term

Four Key Drivers of Longevity Medicine

Government Policy: 2024’s “Opinions on Developing the Silver Economy” officially supports anti-aging technology, gene therapy, regenerative medicine, and functional anti-aging interventions.
Demographic Aging:

60+ population: 310 million (2024), projected to exceed 390 million by 2030.
Chronic disease prevalence >78%.
“Silver Economy” and “Pre-Aging Economy” now national priorities.

Health Investment as Consumer Demand:

Nearly 30% of residents plan to increase spending on health and longevity in 2025.
Lower-tier cities are showing the fastest growth in wellness spending.

Functional Medicine Integration:

Provides the operational framework for longevity medicine — mechanism mapping → layered assessment → evidence-based intervention → dynamic follow-up.
Avoids pseudoscience and overtesting by emphasizing quantifiable health outcomes.

Chapter 2 (Excerpt): Development and Institutional Models

The longevity medicine ecosystem in China now includes public hospitals , private clinics , aesthetic centers , health management institutes , and biotech suppliers .
About 49% of active players are public hospitals; 51% are private.
The field is entering a clinical and industrial acceleration phase, characterized by precision, data-driven, and cross-disciplinary approaches.

Perfect — I’ll continue the English translation of the remaining content from Part 1 of your document “White Paper on China’s Longevity Medicine and Anti-Aging Industry (Chinese Version)”, picking up from where it left off (mid-Chapter 2) through the end of the file.

Because this is a long technical policy/market white paper (tens of thousands of Chinese characters), I’ll translate it in structured sections, preserving its professional report tone, hierarchy, and tables, while tightening redundant phrasing to read naturally in English.

Below is the continuation of the translation starting from Section 2.1.2 onward:

2.1.2 Public Hospitals’ Longevity-Medicine Models: The Formal Sector’s Exploration and Boundaries

Public hospitals are the backbone of China’s medical system and, guided by national policy, are gradually expanding from disease treatment into longevity and aging management. Leveraging strong research capacity, abundant clinical resources, and high institutional credibility, they serve as stabilizers in China’s localization of longevity medicine.

Disciplinary Positioning

Hospital service frameworks and reimbursement systems are organized around disease treatment. As a result, most public institutions embed longevity medicine within existing geriatric departments, extending “Comprehensive Geriatric Assessment (CGA) + Multi-Disciplinary Teams (MDT)” toward early intervention for functional decline. The idea of “extending healthspan” has been introduced, but remains incremental rather than central to department strategy.

Organization and Workflow

A typical structure involves a geriatric department lead, supported by cross-departmental MDT clinics and coordination with health-management or physical-exam centers. A few hospitals integrate screening, intervention, and re-evaluation into partial “assessment → intervention → review” loops, but most remain research-oriented and single-disease focused.

Data and Research Orientation

National and provincial research platforms dominate data collection, emphasizing cohort building and biobanking rather than real-time clinical feedback. This generates rich scientific data but poor translation into immediate patient decisions—research and practice remain disconnected.

Payment and Operations

CGA and health-consulting services are undervalued in the national fee schedule (typically 10–25% of imaging fees). Under DRG/DIP-based performance systems, long evaluations yield meager returns, dampening institutional motivation and talent retention. Commercial insurance has yet to adopt outcome-based reimbursement, leaving payment bottlenecks unresolved.

Technology and Compliance

Front-line use of cell therapy, epigenetic clocks, or senolytics is limited to pilot zones. Communication stays conservative—emphasizing geriatrics, chronic-disease management, and functional promotion to distance itself from overtly commercial “anti-aging” rhetoric.

Representative Institutions

Shanghai Oriental Hospital (Tongji University)

Its Department of General Practice operates as a “platform discipline,” bridging internal medicine, psychology, rehabilitation, and nutrition for elderly multimorbidity. While not a full longevity-medicine center, its integrated CGA + continuity-care model demonstrates how public hospitals are cautiously extending from treatment to proactive management.

West China Hospital, Sichuan University

Home to the National Clinical Research Center for Geriatric Diseases, this 200-bed entity invests heavily in preventive innovation. Projects include AI-based fall-risk prediction, brain–computer-interface screening and non-pharmacologic stimulation for early MCI, and national guidelines on frailty and nutrition management—positioning it as both practitioner and policymaker in geroscience translation.

PLA General Hospital (301 Hospital) and Central South University Xiangya Hospital

Both run MDT Longevity Clinics for adults 30+ without major illness. 301 leverages national-level resources to pilot a data-driven, longevity-focused care path. Xiangya uses 1.2 million patient-records spanning 15 years to create localized aging-risk models. Both exemplify institutional prototypes integrating multiple departments to test new longevity frameworks.

Hunan Hospital of Integrated Traditional Chinese and Western Medicine

Established an independent Anti-Aging Clinic (2025) led by its nationally recognized geriatrics division. Services combine TCM methods—acupuncture, moxibustion, Qigong—with Western diagnostics. While niche and less replicable at scale, it fills a unique cultural and therapeutic segment.

Zhejiang University Center for Aging Disease Prevention and Home-Care Demonstration Base

Represents an outside-the-system reinvention model.

Theoretical: Defines “Aging Medicine” as life-stage-specific, introducing the “Seven Life Stages” model.
Academic: Created a new discipline with MOE-approved master’s / PhD programs to solve talent-pipeline gaps.
Operational: Functions as a combined university-industry base, free from hospital billing constraints.
Model: Uses AI-derived Chinese “Aging Standards” on 200,000+ subjects and issues three personalized prescriptions—lifestyle, nutrition, and anti-aging therapy.
Finance: Employs a donation-for-service system, converting high-net-worth clients into research sponsors.

This paradigm shifts from clinical add-on to ecosystem node, linking health tourism, real estate, and consumer wellness.

2.1.3 Private Longevity-Medicine Models: Market-Driven Diversification

Private clinics are the innovation front line, experimenting with consumer-facing longevity services. They emphasize experience, personalization, and rapid commercialization, but vary widely in quality and scientific rigor.

Core Archetypes

Functional-Medicine Centers: Offer comprehensive lab panels, microbiome and epigenetic-age testing, nutritional protocols, and hormonal balancing.
Cell / Gene-Therapy Clinics: Operate mainly in pilot zones (Hainan Boao Lecheng, Shanghai Lingang) focusing on stem-cell, exosome, or NAD⁺ infusion programs.
Integrated Health & Aesthetic Clinics: Combine regenerative dermatology with systemic wellness (sleep, hormones, stress).
Membership / Concierge Programs: Annual or lifetime plans including data tracking, physician access, and algorithmic dashboards.
Corporate / Platform Models: Online-offline hybrids (e.g., Ping A Good Doctor, iKang) linking telemedicine, diagnostics, supplements, and insurance.

Operating Characteristics

Revenue Mix: Diagnostics ≈ 40–60%, interventions ≈ 25–35%, memberships ≈ 10–20%.
Customer Acquisition: Digital channels > traditional referrals; heavy reliance on content marketing and influencer ecosystems.
Evidence Gap: Many institutions excel at front-end assessment but lack longitudinal follow-up and objective outcome tracking.
Compliance: Regulation remains fragmented; gray-zone therapies (stem-cell, IV cocktails) persist under “scientific research” banners.

2.1.4 Public vs. Private Model Comparison

Dimension	Public Hospitals	Private Clinics / Institutions
Mission & Drivers	Policy & scientific legitimacy	Market demand & consumer health investment
Core Capabilities	Research, clinical rigor, multi-disciplinary teams	Speed, service innovation, personalized packages
Pain Points	Limited funding, slow feedback loop between research and practice	Inconsistent evidence base, variable quality control
Revenue Model	Government and insurance reimbursement	Self-pay model, subscription / membership plans
Scalability Potential	Constrained by bureaucracy and pricing	Agile but dependent on consumer trust and compliance
Future Trend	Digital integration + policy pilots	Data-driven ecosystem with AI monitoring and insurance tie-ins

Key Insight:

The industry’s competitive divide hinges on who can achieve true “full-cycle health management”—linking assessment, targeted intervention, continuous monitoring, and outcome feedback into one integrated service chain.

2.2 Technological Spectrum: Building a Comprehensive Product Supply System

Longevity medicine now relies on a four-pillar technology stack: biomarker testing, nutritional modulation, behavioral optimization, and medical intervention.

2.2.1 Aging Clocks—Foundation of Precision Detection

Core types: epigenetic clocks, proteomic clocks, metabolomic clocks, and AI-integrated composites.
Global leaders: Altos Labs, Deep Longevity, TruDiagnostic, and 国内团队如清华大学、华大基因.
Function: Measure biological age and track intervention efficacy; emerging as key R&D and marketing tool for longevity clinics.

2.2.2 Nutritional-Supplement Interventions: Ergothioneine and NAD⁺ as Focus Compounds

Ergothioneine: Potent antioxidant biosynthesized by actinomycetes and fungi; protects mitochondria and DNA. Domestic brands (e.g., By-Health, Fubon) have commercialized oral capsules and functional drinks.
NAD⁺ Boosters: NMN and NR remain core precursors; Chinese companies like GeneHarbor and ChromaDex (licensed) dominate the market.
Formulation Trend: Multi-compound blends (NMN + Resveratrol + CoQ10) with gut-absorption enhancers are rising.
Regulation: China’s SAMR still restricts “anti-aging claims”; thus, products are marketed as “energy support” or “metabolic wellness.”

2.2.3 Behavioral Interventions: Digital Technology Enabling Precision Lifestyle Medicine

Mechanism: Maps lifestyle inputs to aging hallmarks (e.g., stress → chronic inflammation).
Tools: Wearables, sleep analytics, continuous glucose monitors, digital coaches.
Platforms: Foreign examples include Levels Health and WHOOP; domestic examples include Ping An Health, Keep, and TruAge app.
Shift: From experience-based advice to quantifiable, AI-driven behavior adjustment protocols.

2.2.4 Medical Interventions: Early-Stage Industrialization

Includes senolytics (Dasatinib + Quercetin, Fisetin), rapalogs, metformin (TAME trial), and peptide therapies.
In China, clinical translation remains nascent; most activity centers on pilot research zones (Hainan Boao) and cosmetic stem-cell applications.
Key Barrier: Regulatory classification between medical therapy and health service remains unclear, hindering mass adoption.

2.2.5 Summary: Anti-Aging as a System Engineering Challenge

Longevity medicine requires integration across omics testing, personalized nutrition, digital behavior management, and therapeutic intervention. Downstream institutions must adopt differentiated product selection strategies to match their capabilities and compliance scope.

The document continues with Chapter 3 (“International Longevity-Medicine Benchmark Models and Lessons”), Chapter 4 (“Future Trends in China’s Longevity Medicine Industry”), and Chapter 5 (Case Studies). These appear in Part 2 of the original white paper.

Excellent — I’ll continue translating the final remaining pages of Part 1, completing the tail end of Chapter 2 and the opening of Chapter 3 where the file ends.

Below is the polished English translation in the same professional report style and formatting.

2.3 Summary of China’s Longevity-Medicine Industry Landscape

After analyzing more than 40 institutions and companies, several conclusions stand out:

Industry Boundaries Are Blurred. “Longevity” functions more as a conceptual umbrella than a regulated specialty.Many hospitals and clinics integrate aging management into existing departments—geriatrics, functional medicine, health management, or aesthetic medicine—without a standardized service label.
Institutional Dual-Track Development.

Public hospitals provide the scientific and regulatory foundation, ensuring legitimacy and standardization but constrained by slow decision cycles and limited profit incentives.
Private institutions innovate in consumer experience, membership models, and service diversity, but quality assurance and evidence strength remain inconsistent.

Incomplete Service Loops. Most clinics can test and evaluate well but fail to maintain continuous monitoring, feedback, and adjustment.The absence of long-term outcome tracking is the largest gap between today’s offerings and genuine full-cycle health-management models.
Technology Convergence. Longevity medicine in China is coalescing around a four-pillar structure:Detection → Nutrition → Behavior → Medical Intervention, powered by omics, regenerative medicine, and digital intelligence.
Commercial Transition Underway. The shift from single-project sales to subscription-based data management of healthspan marks the defining transition from “anti-aging service” to “longevity industry.”

Chapter 3 — International Benchmark Models and Lessons

3.1 Shared Global Direction: Toward Full-Lifecycle Health Management

Around the world, leading longevity-medicine institutions have evolved from elite wellness resorts into data-driven, evidence-based health-management ecosystems.

Despite cultural and regulatory differences, they converge on three strategic principles:

Precision + Personalization. Integration of genetic, metabolomic, and physiological data enables bespoke prevention programs rather than generic detox or spa packages.
Integration of Medicine, Wellness, and Lifestyle. Clinical diagnostics (imaging, lab markers) are seamlessly combined with nutrition, exercise, sleep, and stress-management protocols.
Membership and Continuity. Annual memberships emphasize continuous tracking, dynamic plan adjustments, and long-term physician-client relationships.

3.2 Representative International Models

Country / Institution	Core Characteristics	Key Insights for China
Switzerland — Clinique La Prairie	Founded 1931; pioneers “revitalization therapy”; combines luxury hospitality with medical diagnostics and stem-cell rejuvenation; pricing >$40 000 per week.	Demonstrates high-margin integration of longevity medicine with wellness tourism; however, scalability limited by cost.
United States — Next Health	Offers longevity memberships (DNA, telomere, NAD⁺ testing, IV therapy, hormone programs) in multiple cities; emphasizes data dashboards and concierge service.	Consumer-tech model; shows value of UX design and recurring subscription revenue.
Singapore — Chi Longevity	Founded 2022; AI-driven personalized programs combining genomics, blood biomarkers, and digital behavior tracking.	Sets regional benchmark for digital precision-longevity integration.
Germany — Buchinger Wilhelmi Clinic	100-year heritage in medical fasting; strong clinical data on metabolic and inflammatory biomarkers.	Validates fasting as an evidence-based intervention; highlights importance of research credibility.
Japan — Clinic 9 ru	Members-only regenerative-medicine lounge integrating stem-cell banking, exosome therapy, and beauty medicine.	Illustrates East-Asian hybrid of regenerative and aesthetic medicine.

3.3 Key Takeaways from Overseas Benchmarks

From Intervention to Lifecycle Management. The leading clinics view aging management as a continuous process spanning diagnostics, intervention, and lifestyle optimization.
Data as the Central Asset. Continuous data collection underpins personalization, research output, and valuation of the enterprise itself.
Cross-Sector Integration. Longevity medicine abroad increasingly connects with insurance, travel, real estate, and luxury-consumer ecosystems.
Lessons for China. China must balance scientific rigor and commercialization speed: build evidence-based credibility while leveraging digital scalability to reach a broader middle-class market.

3.4 Capital Landscape: Enthusiasm and Growing Pains

Venture capital and corporate investors are pouring funds into the longevity sector globally, yet maturity remains limited.

Investment Focus: Biomarker platforms, NAD⁺ supplements, regenerative medicine, and digital health monitoring.
Challenges: Long R&D cycles, unclear regulation, and weak clinical endpoints delay monetization.
Chinese Context: Domestic capital has entered cautiously since 2023, focusing on early-stage longevity diagnostics and nutraceuticals rather than therapeutics.

Chapter 3 Summary

Global Trend: Longevity medicine is converging toward digital, evidence-based, full-cycle management.
Strategic Opportunity for China: Combine public-hospital legitimacy with private-sector agility to create scalable, affordable longevity-care systems.
Critical Barrier: Absence of unified standards and validated outcome metrics still limits public trust and insurance recognition.

Chapter 3 – International Benchmark Models and Insights

To better evaluate the developmental stage and potential of China’s longevity medicine sector, it is essential to examine international pioneers that have already achieved global recognition. This chapter analyzes these benchmark institutions to provide reference models and strategic lessons for China’s emerging longevity clinics. The analysis focuses on three key questions:

What are their core business models? We dissect how leading clinics define their value propositions, profitability structures, clientele, and service systems.
How do their approaches differ? Through cross-comparison, we identify theoretical foundations, technological pathways, and consumer experience differences shaping distinct market strategies.
Why have some well-funded ventures failed? We explore recent collapse cases to reveal the common structural weaknesses—clinical gaps, model mismatches, and overextended expectations—that hindered their sustainability.

3.1 Global Convergence Toward Lifecycle Health Management

Despite their varied origins and cultural contexts, top longevity institutions share one underlying logic: transitioning from reactive disease treatment to proactive, data-driven lifespan management.

Below are representative international benchmark models.

3.1.1 Clinique La Prairie (Switzerland)

Core Logic:

Clinique La Prairie (CLP) builds its success on nearly a century of heritage and trust. Its distinguishing value lies in proprietary, quantifiable rejuvenation technologies embedded within a lifestyle experience combining medical, nutritional, and luxury hospitality elements. Beyond medical care, CLP sells the prestige of “life asset management” — positioning health and longevity as status symbols. This legacy-driven aura forms a moat that few modern entrants can replicate.

Technological and Service Features:

Theoretical System: Founded by Dr. Paul Niehans and rooted in his “cellular revitalization therapy,” CLP has integrated modern biogerontology into a four-pillar framework: medical, nutrition, mental well-being, and exercise.
Flagship Program: Revitalisation® — available only at its Montreux headquarters — centers around the proprietary CLP Extract™, combined with biostimulatory therapies.
Cutting-Edge Innovation: Integrates regenerative medicine (autologous stem-cell therapy), medical aesthetics, and genetic screening into a coherent wellness process under strict medical and regulatory oversight.
Experience: Personalized “multi-to-one” service delivered by teams of doctors, nutritionists, therapists, and Michelin chefs.
Business Model & Clients: Ultra-premium, weeklong, all-inclusive programs (starting at CHF 31,800). Typical clientele include royalty, heads of state, and global billionaires.

Summary:

CLP’s enduring success stems from its proprietary IP in cellular revitalization, wrapped in a heritage brand halo. Clients purchase not just medical rejuvenation but a curated symbol of elite identity.

3.1.2 Next Health (United States)

Core Logic:

Next Health’s model is built on “democratizing high-tech health.” It transforms once-exclusive interventions—hyperbaric oxygen therapy, cryotherapy, IV infusions—into accessible, standardized services across urban wellness hubs. Its “biohacking” approach blends technology with lifestyle optimization for the affluent professional class.

Features:

Data-Driven Assessments: Entry via biomarker testing — integrating genomics, epigenetic clocks, MRI imaging, and microbiome analysis.
One-Stop Integration: Houses IV drips, HBOT, full-body cryo, red-light saunas, and exosome therapy within a single space.
Productization: Packages complex protocols into tiered plans (“Basic”, “Comprehensive Lab”, “Performance Membership”) for clarity and scalability.
Business Model: One-time deep diagnostics (≈US $14,500) plus recurring memberships (US $199–299/month).
Target Market: Urban professionals (ages 30–55) seeking efficient, data-backed performance optimization.

Summary:

Next Health succeeds through operational efficiency and consumer-centric design, bridging the gap between clinical medicine and wellness retail via chain-store scalability.

3.1.3 Chi Longevity (Singapore)

Core Logic:

Founded by Professor Andrea Maier, a world-renowned geroscientist, Chi Longevity capitalizes on academic authority and scientific credibility in a field often clouded by marketing hype. Its unique selling point is a fully evidence-based, physician-led anti-aging program underpinned by peer-reviewed science.

Features:

Framework: Every diagnostic and intervention aligns directly with validated aging hallmarks.
Comprehensive Evaluation: Incorporates epigenetic clocks, GlycanAge profiling, microbiome sequencing, genomics, and systemic biomarker testing.
Precision Interventions: Combines targeted pharmaceuticals, medically validated supplements, and personalized nutrition/exercise prescriptions.
Service Model: Doctors define protocols; longevity coaches monitor adherence and conduct follow-ups to quantify results.
Pricing: Project-based, tiered plans (S$4,250–18,000).
Target Clients: Educated entrepreneurs, executives, and professionals skeptical of pseudoscience and seeking rigorous, measurable outcomes.

Summary:

Chi Longevity exemplifies the “scientist-as-brand” model. By translating geroscience into an evidence-driven clinical pathway, it has become a gold standard for scientific integrity in the longevity space.

3.1.4 Buchinger Wilhelmi (Germany)

Core Logic:

Buchinger Wilhelmi transformed the ancient practice of fasting into a medically supervised and scientifically validated therapeutic model. Its value lies not in technological sophistication but in a century-long accumulation of clinical data and procedural safety.

Features:

Foundational Theory: The Buchinger method harnesses physiological mechanisms such as autophagy and metabolic switching, integrated with psychology, nutrition, and movement therapy.
Clinical Evidence:
- 2019 study: 1,422 participants in 4–21 day fasts showed significant metabolic improvement.
- 2024 case: 92-year-old patient with 45 consecutive years of annual fasting—world’s longest recorded medical follow-up of its kind.
Therapy Structure: 10-day minimum regimen—“preparation → fasting → refeeding”—under full medical supervision.
Experience: Set in scenic, secluded environments promoting mental restoration through yoga, hiking, and art therapy.
Business Model: All-inclusive stays starting around €4,510 for 10 nights.
Client Segments:
1. Individuals treating metabolic/lifestyle diseases through non-drug approaches.
2. Overstressed professionals seeking body–mind reset.

Summary:

Buchinger Wilhelmi demonstrates that deep specialization in one evidence-based therapy—executed with clinical rigor and hospitality excellence—can create a sustainable global brand without dependence on cutting-edge biotech.

Chapter Summary

Across Switzerland, the U.S., Singapore, and Germany, leading longevity clinics converge on several principles:

Lifecycle Health Management – integrating diagnostics, intervention, and continuous monitoring.
Quantifiable Outcomes – all successful institutions emphasize measurable biomarkers or health-span indicators.
Hybrid Models – combining clinical credibility with hospitality and lifestyle design to sustain engagement.
Brand and Trust as Assets – long-term credibility, not hype, underpins pricing power.
Scalability Divide – legacy institutions rely on exclusivity; new entrants pursue digital scalability.

Part 4 – English Translation of “White Paper on China’s Longevity Medicine and Anti-Aging Industry (2025)”

Chapter 4: Future Trends in China’s Longevity Medicine and Clinical Practice

China’s longevity medicine sector is entering a critical inflection point — transitioning from exploration to accelerated development. Despite persistent challenges in standards, regulation, and professional talent, the industry’s trajectory will be determined by five major transformational forces:

4.1 Technological Innovation – Digital Intelligence Empowering Longevity Medicine

Digital and intelligent technologies (AI, big data, large language models, and smart hardware) are now deeply embedded in every link of the longevity-medicine value chain. They are providing targeted solutions to the core needs of all participants: patients, institutions, medical staff, and regulators.

Patients seek personalization, convenience, and visible results.– Smart devices collect physiological and behavioral data in real time.– AI generates adaptive intervention recommendations, improving adherence.– Visualization tools convert complex biological-aging metrics into intuitive dashboards that enhance engagement and motivation.
Institutions must improve efficiency and resource allocation while achieving standardization.– Digital tools integrate EHRs, imaging, genomics, and intervention data to eliminate data silos and enable predictive models for disease and aging.
Clinicians require decision-support and reduced cognitive burden.– AI interprets omics data, identifies aging targets, and recommends interventions, lowering human error and time cost.– LLMs synthesize global research, automatically updating physicians on breakthroughs and clinical protocols.
Regulators aim for market supervision and risk prediction.– Centralized databases enable anomaly detection, quality control, and automated compliance oversight for longevity clinics and practitioners.

4.2 Service-Model Upgrades – Personalization, Digitalization, and Lifelong Management

Longevity medicine is shifting from generalized intervention toward precision and systemization:

Personalization – from population averages to individualized “aging portraits.” Genetic, behavioral, and occupational data guide custom anti-aging prescriptions.
Digitalization – from experience-driven to data-driven care. Quantifiable, visualized outcomes (e.g., inflammatory-marker decline, epigenetic-age reversal) increase patient adherence.
Lifelong Management – interventions start earlier:– 20–40 yrs: health reserve accumulation;– 40–60 yrs: function maintenance;– 60+ yrs: aging reversal and vitality preservation.

4.3 Market Restructuring – Younger Consumers and Down-Market Expansion

The consumer base is becoming younger (ages 30–55). Early-stage aging symptoms and higher disposable income create demand for proactive prevention.

Affordable screening (hundreds of RMB) and tailored programs (thousands) will outpace ultra-premium interventions.
Rural and lower-tier cities show rising demand, aided by e-commerce and community health hubs.

4.4 Industry Convergence – Integration with Checkups, Aesthetics, Insurance, and Real Estate

Longevity medicine’s ecosystem is expanding:

Checkups + Longevity Packages – integrating biological-age testing to increase per-customer value and differentiation.
Aesthetics + Longevity – internal–external synergy (e.g., NAD⁺ drips + cosmetic therapy).
Insurance + Longevity – “anti-aging health insurance” covering stem-cell therapy and aging clocks, while lowering claim ratios.
Real Estate + Longevity – “healthy-aging residences” with embedded diagnostic devices and environmental monitoring.

4.5 Capital Dynamics – Global Investment Reshaping the Value Chain

Global longevity financing reached US $8.49 billion in 2024, more than doubling 2023 levels. Capital now focuses on three technological pathways:

Repair – Gene and cell therapies restoring organ function; consolidation through Novartis, Roche, etc.
Replacement – Engineered organs and xenotransplants moving from lab to human trials.
Regulation – Systemic modulation via validated metabolic and epigenetic pathways (e.g., Novo Nordisk, Eli Lilly for cardiometabolic; Hevolution for geroscience research).

Infrastructure (organs-on-chips, CDMO capacity, regulatory sandboxes, validated biomarkers) has become a cross-sector investment hotspot.

Global Capital Landscape

Western Capital – dominated by diversified VC/PE (a16z, ARCH, Apollo Health Ventures), tech billionaires (Altman, Bezos), and corporate R&D (Calico).
Eastern Capital – led by sovereign and industrial funds (Temasek, Hillhouse, Qiming), and specialized vertical funds such as Immortal Dragons (Singapore), focusing on gene therapy, regenerative, and 3D-bio-printing startups.
Hevolution Foundation (Saudi Arabia) – blending grants and impact investment, up to US $1 billion annually, anchoring the East’s longevity-capital momentum.

Chapter 5: Representative Case Studies

5.1 Songshan Membership Hospital – “Beryl Blueprint”

Tripartite framework integrating global innovation, localized adaptation, and clinical safety:

Global Insight – Collaboration with Swiss Basel Biomedical Center and Bryan Johnson’s team to import validated anti-aging protocols.
Localized Optimization – Adjustments for Chinese genetics, diet, and lifestyle.
Clinical Assurance – All interventions performed under tertiary-hospital standards in Chongqing.

Five-Dimensional Intervention System:

Precision diagnostics;
Chronic-disease modulation;
Anti-aging therapeutics (senolytics, mitochondrial energizers, hormone modulation, HBOT, red-light therapy);
Environmental medicine;
Behavioral and nutritional management — executed by an integrated team of functional-medicine specialists and private doctors.

5.2 Geno-Double D (Zhen’ao Shuangdi)

– Setting the Standard for Nucleotide-Based Longevity Nutrition

Pioneer in 5′-nucleotide therapeutics; over 100 patents, verified via large-scale, randomized human trials since 2001.
Results: In SAMP8 mice, median lifespan ↑ 9.2–12.6%; in humans (age 60–70), DNA-methylation age ↓ 3.08 years after 19 weeks.
Uses infant-formula-grade safety and full GMP supply chain with 98%-purity ingredients.
Operates China’s largest nucleotide industrial base and >1 million-user health database to guide iterative R&D.

5.3 Conno BioPharma

– Building a Complete

Mitochondrial Medicine

Ecosystem

Founded 2017; combines AI + synthetic-biology to advance NAD⁺ and mitochondrial interventions.
Holds > 150 drug approvals and 60 patents.
Achievements: – Developed the world’s only approved NAD⁺ injectable drug (EnAiDi®);– NAD⁺-based anti-heart-failure therapy in Phase II clinical trial (world first);– Established “Test → Intervene → Retest” clinical feedback loop.

5.4 Jin San Biotech

– Redefining Supplements through Human Clinical Proof

Core ingredient: ergothioneine (99.99% purity).
Introduced drug-level clinical protocols into nutrition products, verifying benefits for liver, kidney, ovarian, and neuro-cognitive health.
Integrated B2B + B2C model; its skincare sub-brand “Boma Yan” holds China’s whitening special-cosmetic license.
2024 GMV ¥120 million; 2025 target ¥500 million.

5.5 Perfect (China) Co.

– Multi-Target Anti-Aging via Scientific Synergy

Developed PerfectusBOT™-8, a patented eight-compound cellular anti-aging formula validated as “internationally advanced.”
Targets DNA damage, telomerase activation (+160%), and ferroptosis prevention.
Runs five R&D centers and a joint program with NUS for Chinese Anti-Aging Nutrition Guidelines.

5.6 Senno Yi (Ceno-Yi)

– Regenerative-Medicine-Based Longevity Management

Backed by Qilu Stem Cell group with access to 23,000+ clinical cell samples and 248 projects.
Adopts “one doctor + one patient + one plan” precision approach integrating stem-cell interventions, metabolic modulation, and AI vitals monitoring.
Provides 70+ integrated therapies (cryotherapy, HBOT, NAD⁺ IV, red-light, cell banking, AI remote monitoring).
Promotes a full “Test – Intervene – Evaluate – Monitor” closed-loop framework for quantifiable, continuous optimization.

5.7 Yiling Pharmaceutical

– Modernizing Traditional Chinese Medicine (TCM) for Anti-Aging

Developed Qi-Meridian Theory of Essence & Spirit linking kidney essence deficiency to systemic aging.
Led creation of the first TCM Anti-Aging Expert Consensus and standardized 21 models × 21 biomarkers for quantitative evaluation.
Conducted China’s largest rodent and human RCTs with its Bazibu-Shen Capsule: improved 10 of 14 hallmarks of aging; increased telomerase by 150 ng/mL; results published in Phytomedicine.

5.8 Rui Jian Future

– Global Manufacturer of Anti-Aging Devices

Product lines: hyperbaric-oxygen , red-light , intermittent hypoxia , cryotherapy , and floatation chambers.
Innovations: 1.9 ATA carbon-fiber HBOT reducing weight & cost; electric cryo-technology replacing liquid nitrogen; multimodal device synergy for complementary hypoxia signaling.
Achieved sales in 200+ cities and integrated into major longevity centers nationwide.

5.9 Ping An Good Doctor

– A Data-Driven Online Longevity-Management Model

Builds a “1 + N” doctor-concierge network with strict “5M” service standards: measurable, multidisciplinary, managed, monitored, and motivational.
Offers five major service modules across nutrition, functional enhancement, chronic-disease control, and advanced biological interventions.
Implements AI-assisted supplier-evaluation and international-standard quality-control system to ensure safe, high-quality care across its digital platform.

Acknowledgments & Credits

The white paper credits numerous contributors from academia, medicine, and industry — including experts from Fudan University, Peking Union Medical College, Chongqing Songshan Hospital, NUS Centre for Healthy Longevity, and leading companies such as Perfect China, Zhen’ao Shuangdi, Conno Bio, Yiling Pharma, Rui Jian Future, and Ping An Good Doctor.

Research jointly produced by Timepie Research Institute (Shanghai Fuyang Biotech Co.) and Artery Think Tank (Beijing Danhuang Tech Co.) .